Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Ghidini

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
Frontiers in Oncology|August 29, 2022
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysisAlessandro Parisi, Riccardo Giampieri, Alex Mammarella, et al.
Cancers|January 21, 2023
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation AnalysisRodolfo Sacco, Daryl Ramai, Raffaella Tortora, et al.
Annals of Surgical Oncology|April 11, 2024
Differences in Lymph Node Metastases Patterns Among Non-pancreatic Periampullary Cancers and Histologic Subtypes: An International Multicenter Retrospective Cohort Study and Systematic ReviewBas A Uijterwijk, Daniël H Lemmers, Giuseppe Kito Fusai, et al.
Therapeutic Advances in Medical Oncology|October 22, 2019
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian studyRossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.
Hepatology (Baltimore, Md.)|December 28, 2019
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ CellsPietro Carotenuto, Somaieh Hedayat, Matteo Fassan, et al.
Clinical Colorectal Cancer|August 12, 2021
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control StudyAlessandro Parisi, Giampiero Porzio, Katia Cannita, et al.
Cancers|May 21, 2020
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" StudyAlessandro Parisi, Alessio Cortellini, Katia Cannita, et al.
European Journal of Human Genetics : EJHG|December 26, 2025
Exome sequencing points to pathogenic ATM variants in gastric cancerLaura L Koebbe, Timo Hess, Stephan L Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal CancerSomaieh Hedayat, Luciano Cascione, David Cunningham, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
Frontiers in Oncology|August 29, 2022
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysisAlessandro Parisi, Riccardo Giampieri, Alex Mammarella, et al.
Cancers|January 21, 2023
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation AnalysisRodolfo Sacco, Daryl Ramai, Raffaella Tortora, et al.
Annals of Surgical Oncology|April 11, 2024
Differences in Lymph Node Metastases Patterns Among Non-pancreatic Periampullary Cancers and Histologic Subtypes: An International Multicenter Retrospective Cohort Study and Systematic ReviewBas A Uijterwijk, Daniël H Lemmers, Giuseppe Kito Fusai, et al.
Therapeutic Advances in Medical Oncology|October 22, 2019
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian studyRossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.
Hepatology (Baltimore, Md.)|December 28, 2019
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ CellsPietro Carotenuto, Somaieh Hedayat, Matteo Fassan, et al.
Clinical Colorectal Cancer|August 12, 2021
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control StudyAlessandro Parisi, Giampiero Porzio, Katia Cannita, et al.
Cancers|May 21, 2020
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" StudyAlessandro Parisi, Alessio Cortellini, Katia Cannita, et al.
European Journal of Human Genetics : EJHG|December 26, 2025
Exome sequencing points to pathogenic ATM variants in gastric cancerLaura L Koebbe, Timo Hess, Stephan L Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal CancerSomaieh Hedayat, Luciano Cascione, David Cunningham, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Pageof 21